Miromatrix Medical Inc.

NasdaqCM:MIRO Stock Report

Market Cap: US$93.0m

Miromatrix Medical Valuation

Is MIRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MIRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MIRO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MIRO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MIRO?

Key metric: As MIRO barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MIRO. This is calculated by dividing MIRO's market cap by their current book value.
What is MIRO's PB Ratio?
PB Ratio6x
BookUS$15.54m
Market CapUS$92.95m

Price to Book Ratio vs Peers

How does MIRO's PB Ratio compare to its peers?

The above table shows the PB ratio for MIRO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.5x
QSI Quantum-Si
0.4x3.3%US$90.3m
OMIC Singular Genomics Systems
0.4x-0.4%US$53.7m
NOTV Inotiv
0.4x31.7%US$72.6m
CELL PhenomeX
0.9x38.2%US$99.6m
MIRO Miromatrix Medical
6x13.5%US$93.0m

Price-To-Book vs Peers: MIRO is expensive based on its Price-To-Book Ratio (6x) compared to the peer average (0.4x).

Price to Book Ratio vs Industry

How does MIRO's PB Ratio compare vs other companies in the US Life Sciences Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
SEER Seer
0.4x11.9%US$134.44m
NOTV Inotiv
0.4x31.7%US$72.55m
No more companies available in this PB range
MIRO 6.0xIndustry Avg. 1.9xNo. of Companies10PB01.63.24.86.48+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: MIRO is expensive based on its Price-To-Book Ratio (6x) compared to the US Life Sciences industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is MIRO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MIRO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MIRO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MIRO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Nov ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Oct ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Sep ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Aug ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Jul ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Jun ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
May ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Apr ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Mar ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Feb ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Jan ’25n/a
US$3.13
0%
4.0%US$3.25US$3.00n/a2
Dec ’24US$3.39
US$3.13
-7.8%
4.0%US$3.25US$3.00n/a2
Nov ’24US$3.31
US$3.13
-5.6%
4.0%US$3.25US$3.00n/a2
Oct ’24US$1.31
US$9.00
+587.0%
66.7%US$15.00US$3.00n/a2
Sep ’24US$1.38
US$9.00
+552.2%
66.7%US$15.00US$3.00n/a2
Aug ’24US$1.41
US$9.00
+538.3%
66.7%US$15.00US$3.00n/a2
Jul ’24US$1.75
US$9.00
+414.3%
66.7%US$15.00US$3.00n/a2
Jun ’24US$0.92
US$9.00
+875.6%
66.7%US$15.00US$3.00n/a2
May ’24US$1.29
US$10.50
+714.0%
42.9%US$15.00US$6.00n/a2
Apr ’24US$1.68
US$13.50
+703.6%
33.3%US$18.00US$9.00n/a2
Mar ’24US$2.78
US$13.50
+385.6%
33.3%US$18.00US$9.00n/a2
Feb ’24US$3.13
US$13.50
+331.3%
33.3%US$18.00US$9.00n/a2
Jan ’24US$2.99
US$15.50
+418.4%
41.9%US$22.00US$9.00n/a2
Dec ’23US$4.15
US$15.50
+273.5%
41.9%US$22.00US$9.00US$3.392
Nov ’23US$3.75
US$15.00
+300.0%
46.7%US$22.00US$8.00US$3.312

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

IQVIA Holdings

US$35.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$191.04

7D

-12.0%

1Y

-6.9%

Collegium Pharmaceutical

US$942.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.75

7D

-5.3%

1Y

16.7%

Teva Pharmaceutical Industries

US$18.7b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.81

7D

-1.8%

1Y

81.3%